Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies. Clinical studies have demonstrated that high-dose decitabine, a hypomethylating agent, results in some cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Hui, Lu, Xuechun, Wang, Xiaohui, Liu, Yang, Guo, Bo, Zhang, Yan, Zhang, Wenying, Nie, Jing, Feng, Kaichao, Chen, Meixia, Zhang, Yajing, Wang, Yao, Shi, Fengxia, Fu, Xiaobing, Zhu, Hongli, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054619/
https://www.ncbi.nlm.nih.gov/pubmed/24963497
http://dx.doi.org/10.1155/2014/371087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054619/
https://www.ncbi.nlm.nih.gov/pubmed/24963497
http://dx.doi.org/10.1155/2014/371087

Ejemplares similares